Clinical Report: PFAS Bioaccumulation: The Biology of Forever

Overview

This report discusses the unique bioaccumulation behaviors of PFAS, which challenge traditional risk assessment models, particularly in their interaction with transporter proteins and phospholipids. It emphasizes the need for new models to accurately assess long-term, low-level exposures to PFAS in humans.

Background

Per- and polyfluoroalkyl substances (PFAS) are persistent environmental pollutants linked to various health risks, including cancer, liver damage, and immune system effects. Understanding their bioaccumulation is crucial for evaluating their long-term effects on human health, particularly as they are commonly found in drinking water and food sources. Current risk assessment models may not adequately represent the complex interactions of PFAS within the human body.

Data Highlights

Key Findings

• PFAS interact with transporter proteins and phospholipids, differing from traditional persistent organic pollutants (POPs).
• Current risk models based on lipid accumulation do not apply to PFAS due to their unique biological behavior.
• Long-term, low-level PFAS exposure requires new risk assessment models for accurate health impact evaluation.
• PFAS exposure has been linked to various health issues, including disruptions in metabolic and immunologic pathways.
• PFAS are commonly detected in human blood and breast milk, raising concerns about infant exposure.

Clinical Implications

Clinicians should be aware of the limitations of existing PFAS risk assessment models and consider the unique bioaccumulation behaviors of these substances when evaluating patient exposure. Specific actions include recommending regular monitoring of PFAS levels in at-risk populations and staying updated on clinical guidelines.

Conclusion

The understanding of PFAS bioaccumulation is evolving, necessitating updated models for risk assessment. Accurate representation of PFAS behavior in the human body is critical for public health and safety, and ongoing research and monitoring are essential.

References

1. the analytical scientist, PFAS: New Frontiers, Emerging Solutions, 2026 -- PFAS Bioaccumulation: The Biology of Forever
2. Archives of Toxicology, Role of Per- and Polyfluoroalkyl Substances in Cancer Development, 2024 -- Role of PFAS in Cancer
3. Archives of Toxicology, Concentrations of PFC/PFAS in Human Breast Milk and Infant Exposure via Lactation, 2025 -- PFAS in Breast Milk
4. the asco post, PFAS Contamination in Drinking Water May Be Linked to Several Rare Cancers, 2025 -- PFAS and Cancer Links
5. Clinical Evaluation and Management: PFAS Information for Clinicians - 2024 | PFAS and Your Health | ATSDR -- Clinical Guidelines for PFAS
6. Clinical Evaluation and Management: PFAS Information for Clinicians - 2024 | PFAS and Your Health | ATSDR
7. Global Serum Per- and Polyfluoroalkyl Substances Exposures and Their Correlation with Lipids: A Systematic Review and Meta-Analysis - PubMed
8. April 2024